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Abstract
Medical science is a field of study that is relevant to all people, but the development of 
pharmaceutical, biomedical and life science is of particular importance. In these fields, 
further studies are being established to determine with incredible accuracy the quantities 
and concentration of inorganic elements and organic compounds, such as nucleotides, 
sulphur and phosphorous containing peptides and proteins, to be used in all kinds of 
drugs. Since 1980, inductively coupled plasma-mass spectrometry (ICP-MS) has emerged 
as a new and powerful technique for elemental and isotopic analysis. It provides a means 
for the analysis of an extremely wide range of elements and the co-analysis of most ele-
ments in the periodic table. It can also be used for qualitative, quantitative and semi-
quantitative analysis and for the measurement of isotopic ratios through mass-to-charge 
ratios. In recent years, ICP-MS has emerged as the best technique for the quantification 
of inorganic impurities in pharmaceutical and biomedical applications. This chapter 
focuses on introducing the applications of ICP-MS in the pharmaceutical and biomedical 
fields. Some problems facing ICP-MS are also presented at the end of this chapter.
Keywords: pharmaceutical analysis, biomedical analysis, inductively coupled  
plasma-mass spectrometry (ICP-MS)
1. Introduction
Within the field of pharmaceuticals, two fundamental issues are necessary for drug therapy: 
safety and efficiency. The impact of elemental impurities in drugs must be investigated using 
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pharmacological and toxicological profiles so that the safety requirements and dosage forms 
of bulk drug scan be determined. This is vital because unwanted pharmacological and toxi-
cological effects may result from elemental impurities and improper drug dosage forms. As 
such, all products intended for human consumption must be characterised as completely as 
possible to ensure quality and safety and to ensure that elemental impurities are being moni-
tored and controlled. Thus, pharmaceutical analysis is one of the most important activities 
related to ensuring the safety of drugs [1].
1.1. Heavy metals in drugs
During the synthesis of pharmaceuticals, inorganic impurities can result from several different 
sources and phases, including solvents, raw materials, reagents, catalysts, electrodes, reaction 
vessels, plumbing and other equipment used. These impurities are often a result of the manufac-
turing process. Routinely monitored as impurities in several drugs are cadmium, copper, chro-
mium, mercury, iridium, molybdenum, nickel, osmium, lead, tungsten, palladium, platinum, 
rhodium, and ruthenium and vanadium and their derivatives [2]. For the synthesis of many 
pharmaceuticals, tungsten-containing catalysts are used in the intermediate reaction process. In 
the pharmaceutical industry, monitoring heavy metals is an important activity for both reaction 
intermediates and final drug substances, not only because of their ability to catalyse decomposi-
tion but also because of their potential for toxicity. Even at very low doses, heavy metals such as 
lead, cadmium, mercury and chromium pose a serious health risk when used for pharmaceutical 
purposes [3]. Long exposures can cause physiological and behavioural issues. For instance, daily 
exposure to 0.06 mg of lead for a period of 1 month is sufficient to cause long-term problems 
such as kidney impairment, demineralization and obstructive lung disease. In pharmaceutical 
and biomedical substances, the presence of heavy metals is monitored and limited by regulatory 
authorities. Tests are performed to ensure that no inorganic-based reagents or contaminates are 
introduced into the drugs at any step during the manufacturing process. The determination of 
residues of metal catalysts and reagents has moved increasingly into the focus of regulatory 
guidance within the last 5 years [4]. The European medicines agency has published guidelines 
on the specification requirements for inorganic metal catalysts and reagents [5]. The United 
States Pharmacopoeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP) and 
Japanese Pharmacopoeia (JP) have proposed the collective monitoring of the total metal content 
in pharmaceutical products. For example, the EP has proposed a limit of 20 μ.g/g of platinum in 
calcium folinate. In aqueous solutions, metal sulphide precipitation results in a clear visual dif-
ference of colour, but this are not the case for similarly treated standard metal solutions. In both 
cases, determining the exact presence of heavy metals is a process that is time consuming and not 
selective, specific or accurate. Thus, there is a great need to develop a highly sensitive and more 
selective technique to determine the presence of heavy metals in pharmaceutical substances and, 
accordingly, to ensure the safety and efficacy of drugs intended for human consumption.
1.2. Atomic spectrometric techniques used in pharmaceutical and biomedical 
analysis
Spectrophotometric techniques are widely used for trace elemental analysis, including 
atomic absorption spectrophotometer (AAS), inductively coupled plasma-atomic emission 
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 spectrophotometer (ICP-AES) and inductively coupled plasma-mass spectrometry (ICP-MS) 
[3, 6]. AAS is used extensively, often for analysing different samples. Flame-AAS (F-AAS) 
or low graphite furnace (GF-AAS) is used for samples with a high concentration of metals. 
Because of its high detection limit, the application of this technique to the analysis of impuri-
ties is limited. However, each metal present can be individually analysed to a high level of 
specificity because of the hollow-cathode lamp used.
ICP-AES is an important technique for the trace elemental analysis of pharmaceutical samples 
[7, 8]. While it is a powerful technique for multielemental analysis, it does suffer from spectral 
interferences and low levels of accuracy. At present, ICP-MS has emerged as the most power-
ful, sensitive and selective technique for the determination of elemental impurities in trace and 
ultra-trace concentrations in pharmaceutical and bulk drug substances. Hence, ICP-MS pro-
vides a major service to the pharmaceutical and bulk drug industries in allowing them to iden-
tify and quantify elemental impurities. However, there are limitations to ICP-MS in that it is 
very expensive and lacks certified reference standards for most drugs and pharmaceutical prod-
ucts. The pattern of the various spectrometric techniques used recently is shown in Figure 1.
2. Principle and instrumentation of ICP-MS
The hyphenated ICP-MS principle and construction are essentially identical. Plasma employs 
the ionisation source for the ICP, and positively charged ions detect the mass analyser in the 
mass spectrometer (MS). Generally, argon gas is used to generate plasma at a high frequency 
(30 MHz), with energy in the range of 1000–2000 W, since in the periodic table most  elements 
Figure 1. Usage pattern of different spectrophotometric techniques in detection of trace metals in drugs and pharmaceutical 
industry.
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excite and ionise at plasma temperatures in the range of 6000–10,000 K. The torch is made 
with quartz and consists of three concentric tubes through which the argon flows. The peri-
odic table shown in the Figure 2 makes multielemental analysis possible. A schematic dia-
gram of the ICP-MS instrumentation is shown in Figure 3.
When a sample is introduced into the plasma, it goes through desolvation, vaporisation, 
atomisation and ionisation before entering the mass analyser. There are many methods for 
introducing the samples, which can be solid, liquid or gas, into the plasma. Most commonly, 
liquid samples are introduced using pneumatic nebulization.
From ICP, the MS extracts the ions at a low pressure, via sampling and skimmer cones. Later, 
ions travel towards the quadrupole mass analyser through a series of ion lenses. Positively 
charged ions are then separated according to the mass-to-charge ratio. Ions can then be 
detected by an electron multiplier and amplified. The quadrupole mass analyser is widely 
used ICP-MS, and the double-focusing field mass analyser is used to achieve more separation 
and to decrease isobaric interference (such as 40Ar, 35Cl+ interference with 75As+). A speciation 
analysis can also be performed using time-of-flight mass spectrometry (TOFMS). Another pos-
sible separation technique, the introduction of samples into the source of ICP at atmospheric 
pressure makes its possible of coupling separation techniques to ICP-MS. This decreases the 
isobaric overlap of the high-resolution mass analyser and interests ions with different mass-
to-charge ratios differently via chemical reaction. The percentages of the different elements 
analysed by ICP-MS in pharmaceutical substances and bulk drugs are shown in Figure 4.
Figure 2. Elements detectable by ICP-MS analysis.
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Figure 3. Schematic diagram of inductively coupled plasma-mass spectrometer: 1. Liquid sample, 2. Pump, 3. Nebuliser, 
4. Spray chamber, 5. Argon gas torch inlets, 6. Torch, 7. Sampler cone, 8. Skimmer cone, 9. Ion lenses, 10. Quadrupole 
mass analyser, 11. Electron multiplier detector, and 12. Data collection.
Figure 4. Individual elements analysed by ICP-MS in pharmaceutical substances and bulk drugs.
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3. Sample preparations
Samples are normally prepared using dissolution or digestion with a low concentration of 
mineral acids [9, 10]. For the reproducibility of volatile, low-concentration and low-volume 
 elements, microwave digestion is better than acid digestion. However, microwave digestion 
and acid digestion are both appropriate for pharmaceutical samples due to the volatility of 
some metals and trace detection limits. The laser ablation technique [11] can be used for solid 
samples. Some of the sample preparation methods are summarised in Table 1.
Element Bulk drug/
formulation
Procedure Medium Calibrationa Reference
W Bulk drugs Dissolution 80:20 (v/v) HNO
3
EC with 209Bi 
for IS
[12]
Fe Methotrexate Microwave-
assisted
H
2
SO
4
 + HNO
3
EC with 56Fe [13]
Pd, Pt, Rh Enalapril maleate
Calcium folinate
Levodopa
Dissolution
Dissolution
Dissolution
1:1 HNO
3
, 0.3 M,
0.2 M HNO
3
, 0.2 M 
HNO
3
EC with In 
for IS
[14]
Pd Fosinopril sodium Dissolution 25% (v/v) 2-butoxy 
ethanol and water
EC with In 
for IS
[15]
69 elements Drug substances, 
intermediate and 
raw materials
Dissolution, 
sonication
80% (v/v) HNO
3
EC [16]
Cr, Ni, Sn, Pb Vitamin E Microwave 
digestion
Emulsion 
preparation
HNO
3
 + H
2
O
2
, 
Triton X + Tetralin
EC, Y, In and 
Tl for IS
[17]
Na, Br, Pd, Ba, I Methamphetamine 
HCl
Dissolution H
2
O EC [18]
As, Se, Mo, Ru, Pd, Cd, In, 
Sn, Sb, Pt, Hg, Bi, Ag.
API with various 
functionalities
Dissolution 2-butoxy ethanol/
water (25:75 v/v)
EC with Co, 
Au and Rh 
for IS
[19]
Cr, Cu, Mg, Mn, Mo, P, 
Se, Zn.
Multimineral and 
multivitamin
Microwave 
digestion
HNO
3
EC with Co 
for IS
[20]
Li, B, V, Cr, Mn, Ni, Zn, Cu, 
Br, Sr, Sn, Ba, Pt, and Pb
Ecstasy tablets Dissolution 1% (v/v) HNO
3
EC with Rh 
for IS
[21]
Ti, Cr, Mn, Fe, Co, Ni, Cu, 
Zn, Cd, Hg, Pb
Dicyclomine HCl,
Ethambutol,
Pyrazinamide,
Furazolidone
Dissolution 
and digestion
5% (v/v) HNO
3
HNO
3
 + H
2
O
2
 + H
2
O
EC [22]
As, Cd, Hg, Pb Dietary 
supplements
Microwave 
digestion
HNO
3
Ec with Rh, IN 
Lu, Bi for IS
[23]
aEC: external calibration; IS: internal standardisation.
Table 1. Sample preparations procedures for analysis of trace elements in pharmaceutical substances and bulk drugs 
using ICP-MS.
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4. Applications
4.1. Applications of ICP-MS in pharmaceutical samples
4.1.1. Determination of multielements in drugs and pharmaceutical substances
Supplements in the form of gluconate contained the lowest concentration of cadmium, which 
was detected in many zinc supplements, according to ICP-MS [26]. In calcium supplements, 
cadmium and lead were detected using ICP-MS, F-AAS and electrothermal-atomic absorption 
spectroscopy (ETAAS) [27]. Using GF-AAS and inductively coupled plasma-optical emission 
spectroscopy (ICP-OES), iron and palladium were detected in the bulk drug methotrexate; 
and the results were compared which obtained from ICP-MS [13]. To avoid polyatomic inter-
ferences before quadrupole mass analysis (such as 40Ar, 16O with 56Fe), hexapole collision cell 
was used. Using ICP-MS, lead and its isotope ratio was investigated in antacids and calcium 
drug supplements using rhenium as an internal standard [28–30].
Tungsten has been identified in bulk drug substances and their intermediates, with bis-
muth used as an internal standard [31]. With the help of different isotopes, spectral interfer-
ences have been monitored in bulk drug substances. In bulk drug samples, ICP-MS was also 
used to detect up to 2500 ppm of tungsten [31]. The ICP-MS results are in accordance with 
those of microwave induced plasma-mass spectrometry (MIP-MS). Hence, ICP-MS has been 
used for the expeditious screening for inorganic impurities such as rhodium, palladium, 
platinum, beryllium, vanadium, manganese, cobalt, nickel, copper, zinc, molybdenum, cad-
mium, tin, thorium and lead, using Rh103, Pd105, Pd106, Pt195 and In isotopes as an internal 
standard.
4.1.2. Multielements in synthetic drugs
Sodium, bromine, palladium, barium and indium have been investigated in metham-
phetamine hydrochloride, which is prepared using catalyst and reagent methods [18]. 
Barium, palladium, bromine, iodine and sodium were detected by Emeds and Nagais using 
ICP-MS. The levels of these elements in N-methylamphetamine were measured, and the 
results were compared with neutron activation analysis (NAA). ICP-MS has been used to 
detect multielements in synthetic drugs; these elements include arsenic, selenium, cad-
mium, indium, tin, antimony, lead, bismuth, silver, palladium, platinum, mercury, molyb-
denum, and ruthenium. Several ICP-MS procedures have been reported for performing 
single and multielemental analysis in drugs and pharmaceutical substances, as shown in 
Table 2.
4.1.3. Multielements in herbal drugs
In herbal drugs such as dietary supplements, inorganic impurities are a major concern due to 
their major toxicity and impurities (e.g., As, Cd, Hg and Pb) [23]. Normally, dietary supple-
ments are analysed using high-resolution ICP-MS. Microwave digestion method is also an 
accepted method according to National Institute of Standards and Technology (NIST) refer-
ence materials.
Biomedical and Pharmaceutical Applications of Inductively Coupled Plasma-Mass Spectrometry…
http://dx.doi.org/10.5772/intechopen.74787
137
Drug/formulations Elements MDL Detector Reference
Dicyclomine 
HCl, Ethambutol, 
Pyrazinamide,
Furazolidone
Ti, Cr, Mn, Fe, Co, 
Ni, Cu, Zn, Cd, 
Hg, Pb
Not reported Varian ultramass 700 [22]
Neusilin Al, Mg 40 and 6 μg/g Laser ablation system: CETACLSX-100, 
Perkin-Elmer SCIEX, ELAN 
6000ICP-MS
[23]
Drug substances, 
intermediate and 
raw materials
69 Elements 0.004–19 ppm Elan 6000 ICP-MS, 1300 Wrf, cross 
flow nebuliser, Scott spray chamber
[16]
Vitamin E Cr, Ni, Sn and Pb 3.02, 0.22, 2.92, 
0.07 ppb (emulsion) 
0.13, 0.05, 0.70, 
0.08 ppb (15% HNO
3
)
Aglient 7500 ICP-MS, 1100 Wrf 
Meinhard nebuliser
[17]
Methamphetamine 
HCl
Na, Br, Pd, Ba, I Not reported Seiko ICP-MS SPQ-6100, 1.35 kW 
quadrupole
[18]
Fosinopril sodium 
(monopril)
Pd 0.1 μg/g Plasma Quad PQ11 Turbo plus ICP-MS 
jacketed Scott type spray chamber, 
cooled to 5°C, platinum sample cone
[15]
Enalapril maleate, 
calcium folinate, 
levodopa
Pd, Pt, Rh 15, 2.8, 2.5 ng/g Plasma Quad II STE peristaltic pump: 
spray chamber: double pass, water 
cooled (10°C)
[14]
API As, Se, Mo, Ru, 
Pd, Cd, In, Sn, Sb, 
Pt, Hg, Bi, Ag.
0.37, 0.42, 0.08, 0.2, 
0.18, 0.03, 0.17, 0.35, 
0.16, 0.03, 1.82, 1.51, 
0.15 μg/g
VG Plasma Quad PQII TURBO plus, 
ICP-MS and Micro mass platform 
ICP-MS
[19]
Multimineral and 
multivitamin
Cr, Cu, Mg, Mn, 
Mo, P, Se, Zn
48.3, 47.1, 24.3, 9.0, 
43.2, 750, 24, 109 ng/l
VG Plasma Quad 3 ICP-MS, 1380 W [20]
Methotrexate Fe 0.2 μg/g Thermo elemental ICP-MS with 
collision cell technology
[13]
Bulk drug 
substances
W 0.04 ppm Perkin-Elmer Elan 6000 ICP-MS, AS-91 
auto sampler 1300rf
[12]
Ecstasy tablets Li, B, V, Cr, Mn, 
Ni, Zn, Cu, Br, Sr., 
Sn, Ba, Pt, and Pb
Not reported Perkin-Elmer SCIEX Elan 6000 
ICP-MS, Gibson peristaltic pump, 
rf1000W, nebuliser ryton cross flow 
with gem tips
[21]
Dietary 
supplements
As, Cd, Hg, Pb 8.2, 18, 140, 25 ng/l Micro mass Plasma Trace-2 HR 
ICP-MS, rf1350W
[23]
Chinese medicinal 
material
As, Hg 0.19, 0.32 μg/l ELAN 6000 ICP-MS rf 1000 W, HP 
4500 ICP-MS rf 1200 W, Babington 
type cross flow nebuliser, peristaltic 
pump, double pass spray chamber
[24]
Dietary 
supplements
Pb, Hg, Cd, As, U, 
Cr, V, Cu, Zn, Mo, 
Pd, Sn, Sb, Tl, W
Not recorded Micro mass platform ICP-MS 
Meinhard concentric nebuliser
[25]
Table 2. Determination of single and multielements in drugs and pharmaceuticals using ICP-MS.
Drug Discovery - Concepts to Market138
An analysis of arsenic and mercury in Chinese Medicinal Materials (CMM) was completed 
using ICP-MS, with trace amounts of both arsenic and mercury found [24]. This is notable 
because of the leaching characteristics of these elements. Mercury and arsenic are often used 
in traditional Chinese medicine (TCM) and have insoluble sulphides due to the low leaching 
efficiency of the cinnabar or realgar minerals in the drug formulations [24]. ICP-MS has been 
used to determine elemental impurities in plant and dietary materials, [25] and indium has 
been used as an internal standard.
In herbal materials, quality and safety is of major importance. Lead, arsenic and cadmium, in 
particular, are of considerable importance in herbal materials such as mineralised mint, nettle 
and black-wrack leaves [32]. In herbal materials, arsenic, cadmium and lead have been quan-
titatively determined to be in the range 0.2–200 ppb, 0.1–20 ppb and 0.1 ppb–10 ppm, respec-
tively. Also, arsenic was investigated in uncoated TCM using ICP-MS with high-pressure 
microwave digestion [33].
4.2. Application of ICP-MS in biomedical analysis
The continuous improvement of techniques and their applications in the life sciences sphere, 
including the combining of organic and inorganic MS, has helped to further advance the field. 
For inorganic MS and life sciences, ICP-MS has emerged as a key technique in biomedical 
research. In this section, some of the applications of ICP-MS in the biomedical field will be 
explored.
4.2.1. Analysis of DNA using ICP-MS
The development of cancer cells and modifications in DNA are commonly caused by the 
chemical modification of nucleobases, such as styrene oxide. The detection of cancer and 
DNA adducts is essential, and there are various methods based on standard reference mate-
rials, such as mass spectrometry, 31P labelling and immunoassays (however, these are not 
readily available as they have not been made for three decades). The problem is that iden-
tification and unknown modification is not possible. Such problems as selectivity, sensitiv-
ity, and qualitative and quantitative technique soften arise when using internal standards, 
regardless of their structure.
For example, ICP-MS quantitatively engages phosphorus signals in modified nucleotides 
using bis(4-nitropenyl)phosphate (BNNP) as an internal standard [34, 35]. Hence, ICP-MS 
has independent elemental selectivity, sensitivity and detection capability.
4.2.2. Analysis of proteins using ICP-MS
In recent years, ICP-MS was used extensively in the field of proteomics [36] for the determina-
tion of metal concentrations in proteins and biomedical analysis. In these studies, similarly, 
bromine was detected quantitatively in rats and human plasma metabolism using ICP-MS [36]. 
In biological systems, and especially in proteins, metals play an important role as cofactors. 
Without proteins, there will be an absence of essential metals such as manganese, iron, cop-
per, cobalt, molybdenum and zinc and of essential non-metals such as selenium and iodine. 
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A deficiency in these metals and non-metals cause diseases as well as catalytic cytotoxic reac-
tions. The field of proteomics determines the metals contained in proteins and, therefore, 
faces the challenging task of identifying metals and their concentrations, which requires a 
more selective, sensitive and powerful analytical technique. ICP-MS has been used to identify 
phosphorus, iron, zinc and copper quantitatively within brain proteins and has been used 
in the study of neurodegenerative diseases [37, 38]. ICP-MS also represents a powerful tech-
nique for the detection of copper, iron and zinc in proteins in the study of Alzheimer’s disease 
and has also analysed copper, zinc and iron with respect to 54Fe/55Fe, 65Cu/63Cu and 67Zn/64Zn.
4.2.3. Analysis of trace elements in human health
Everybody knows that in human health, some of the elements are essential and others are 
toxic. However, the benefits and risks of each element depend on the quantity of the intake, 
the accumulation, the mobility of the element, the storage and interaction of the element in 
metabolites, the oxidation number, the metal-ligand ratio and the complexity of its interaction 
with different elements. ICP-MS has become one of the most powerful techniques for elemen-
tal speciation studies. In HepG2 cell and liver cell lines, copper and its isotope ratio 63Cu/65Cu 
has been measured accurately using ICP-MS [39], and in human blood and livers, iron and 
its isotopic ratio has been measured. In the liver, iron and its isotopic composition has been 
found to be higher than that of the blood and muscles [40].
In vivo, many essential and non-essential elements can interact with each other. Because of 
these interactions, it is important to anticipate deficiency and excess and to know elemental 
toxicity levels. To use elemental analysis to determine concentrations, ICP-MS has proved to 
be an advantageous technique. ICP-MS has been used to identify trace elements that are toxic 
and those that are essential [41–44]. In human blood and serum, many trace elements can be 
found, including cobalt, copper, zinc, selenium, rubidium, rhodium, palladium, cadmium, 
tungsten, platinum, mercury, thallium and lead. Both blood and serum selenium correlated 
with blood can contain the trace elements lead, mercury, copper and zinc.
5. Brief solution to problems in the application of ICP-MS
ICP-MS is a good analytical method when compared to the other analytical methods available. 
However, it is not without its drawbacks. These include signal fluctuation and the matrix effect, 
which occurs when elements that are very close in terms of mass number experience an indis-
tinguishable influence [45]. The matrix effect might be a result of the plasma, the deposition 
of salts in the orifices, ion extraction or the internal standard [46]. The matrix effect can cause 
severe interference, but it can be eliminated by selecting a matching standard for the matrix of 
the isotope being diluted or by ensuring a greater dilution of the specimen. It can be of particu-
lar concern for double electric charge ions, such as barium and cerium, as these elements have 
low second ionisation energy levels. Oxides can be controlled by elevating the temperature of 
the plasma or slowing the rate of flow. Polyatomic ions and isobars can impede the detecting 
the mass-to-charge ratio via quantitative analysis, making them very important to analysts.
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6. Conclusion
ICP-MS has the power required to sensitively analyse the presence of trace elements; the 
method has low detection limits, allows for more selectivity of elemental mass, provides 
insight into the isotope ratio and performs ultra-trace elemental detection. It can be used 
for the elemental analysis of inorganic and organic elements in all kinds of drugs, including 
nucleotides, sulphur, and phosphorus containing proteins, providing both a qualitative and 
quantitative determination with accuracy, making it a vital method for trace element analysis 
in the pharmaceutical and biomedical fields.
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